The Preliminary Study Of B Cell-activating Factor Level And Clinical Significance In T1DM Patients

Objective To investigate the serum level and clinical significance of B cell-activating factorbelonging to the TNF family (BAFF) in patients with type1diabetes mellitus(T1DM).Methods26T1DM patients,25T2DM patients and20healthy subjects were enrolled in ourstudy. Serum BAFF were tested with emzyme-linked immunosorbent assay (ELISA).Results1.The serum BAFF level in T1DM group were higher than T2DM group and controlgroup(297.54vs218.80vs199.20，F=4.257，P <0.05).The serum BAFF level in T2DM group washigher than the control group (15.82vs.12.24,P＜0.05); But there was no significant differencebetween T2DM group and control group)(218.80vs199.20，P>0.05).2.In T1DM group, the serum BAFF level were positively correlated with HbA1c(r=-0.506，P=0.008)while negatively correlated with FCP(r=-0.506，P=0.008); There was no significantrelationship between serum BAFF levels and FBG、2hPG、2hCP in this study. the serum BAFFlevel were positively correlated with TC and TG (r=-0.413,0.581,P=0.036,0.002). In T2DM group,the serum BAFF level were positively correlated with HbA1c、 FBG(r=-0.495，0.435，P=0.012,0.030)while negatively correlated with FCP(r=-0.516，P=0.008).There was no significantrelationship between serum BAFF levels and other clinical data in this study.3.The regression equation of multivariate stepwise regression analysis: FCP=0.494－0.001×BAFF；R2=0.256，F=8.241，P=0.008. This equation shows tha the serum BAFF level werenegatively correlated with FCP. The higher concentration of BAFF, the lower level of FCP.Conclusion1. BAFF may be closely related with elevated blood glucose and decreasing C-peptide inT1DM patients.2. BAFF may be associated with dyslipidemia in T1DM patients.